U.S. License Holder:
Eli Lilly
Date of License:
November-26-2002
Last Update:
Dec-15-2024
FDA-Approved Indications
FORTEO (teriparatide) is recombinant human parathyroid hormone analog (1-34), [rhPTH(1-34)] indicated for:
Treatment of postmenopausal women with osteoporosis at high risk for fracture;
Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture;
Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture.
aBLA / 505(b)(2) Activity
aBLA / 505(b)(2) Approved by FDA
Bonsity: Pfenex / Alvogen (October-2019); Teriparatide Teva: Teva (November-2023) Teriparatide Apotex: Apotex / Ambio (November-2023)
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In Canada
Apo-teriparatide (Apotex) (May-2020) Osnuvo (Avir Pharma) (January-2020) Teva-teriparatide (Teva) (June-2020)
Biosimilars Approved In The E.U.
Kauliv (Strides Pharma) (January-2023)Livogiva (Theramex Ireland Limited /Pfenex) (August-2020) Movymia (STADA Arzneimittel) (January-2017) Sondelbay (Accord Healthcare) (March-2022) Teriparatide Sun (Sun Pharmaceutical) (Novmber-2022) Terrosa (Gedeon Richter) (January-2017)
Biosimilars Approved In Australia
Teriparatide GH® / Teriparatide LAPL® / Teriparatide LUPIN® (Generic Health) (April-2023) Teriparatide RBX / Teriparatide SUN (Sun Pharma) (May-2024)Terrosa® (Gedeon Richter) (December-2020)
Biosimilars Approved In Japan
Teriparatide BS (Gedeon Richter Plc / Mochida Pharmaceutical Co., Ltd.) (September-2019)
Biosimilars Approved In South Korea
Teribone (Dong-A St. Co., Ltd.) (November-2015) Terrosa (Daewon Pharmaceutical) (November-2019)